4D Molecular Therapeutics, Inc. reports $28.7 million Q1 loss

4D Molecular Therapeutics, Inc. [FDMT] has reported fiscal Q1 loss of $28.70 million.

On a per-share basis, the DE based company said its diluted earnings are $0.88.

The Biological Products, Except Diagnostic Substances firm posted revenue of $0.30 million in this period.